Most Read Articles
Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Christina Lau, 5 days ago

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

4 days ago
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Higher GPS linked to adverse pathology risk in men on active surveillance

09 Oct 2019

A higher Genomic Prostate Score (GPS) is a predictor of an increased risk of adverse pathology in patients who undergo radical prostatectomy after a period on active surveillance, as in those who undergo immediate prostatectomy, reports a study. The GPS is also associated with biochemical recurrence after radical prostatectomy.

The investigators identified patients on active surveillance at University of California-San Francisco who had Gleason score 3 + 3 or low volume (33 percent of fewer positive cores) Gleason score 3 + 4 prostate cancer, GPS testing at diagnostic or confirmatory biopsy, clinical stage T1/T2, prostate-specific antigen <20, and a clinical CAPRA (Cancer of the Prostate Risk Assessment) score <6.

Adverse pathology, defined as Gleason score 4 + 3 or greater, stage pT2a or greater or pN1, was the primary outcome. Biochemical recurrence, defined as two consecutive prostate-specific antigen measurements >0.05 ng/ml following radical prostatectomy, was the secondary outcome.

In total, 215 men were included. Of these, 179 (83 percent) were at low risk and 36 (17 percent) were at intermediate risk by CAPRA scoring. The median GPS was 26.4 (interquartile range, 18.8–34.6).

Multivariate analysis revealed an association between a higher GPS and an increased risk of adverse pathology at delayed radical prostatectomy (hazard ratio [HR] per 5 units, 1.16, 95 percent CI, 1.06–1.26; p<0.01). An association also existed between a higher GPS and an increased risk of biochemical recurrence (HR per 5 units, 1.10, 1.00–1.21; p=0.04).

“The GPS (Oncotype Dx® Genomic Prostate Score) test is an RNA expression assay which can be performed on prostate biopsies,” according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Christina Lau, 5 days ago

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

4 days ago
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.